Loading...

FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

Published
11 Feb 25
Updated
10 Sep 25
AnalystConsensusTarget's Fair Value
UK£27.97
3.8% undervalued intrinsic discount
10 Sep
UK£26.90
Loading
1Y
28.7%
7D
1.9%

Author's Valuation

UK£27.973.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on10 Sep 25
Fair value Increased 4.43%

The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.

Shared on26 Mar 25
Fair value Increased 9.53%

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Decreased 7.79%

AnalystConsensusTarget has increased revenue growth from 3.4% to 4.0%, increased profit margin from 8.0% to 9.5% and decreased future PE multiple from 33.4x to 27.5x.